155 related articles for article (PubMed ID: 36869888)
21. Neurological management and work-up of neurotoxicity associated with CAR T cell therapy.
Möhn N; Bonda V; Grote-Levi L; Panagiota V; Fröhlich T; Schultze-Florey C; Wattjes MP; Beutel G; Eder M; David S; Körner S; Höglinger G; Stangel M; Ganser A; Koenecke C; Skripuletz T
Neurol Res Pract; 2022 Jan; 4(1):1. PubMed ID: 35000613
[TBL] [Abstract][Full Text] [Related]
22. Neurological adverse effects of chimeric antigen receptor T-cell therapy.
Saleki K; Mohamadi MH; Alijanizadeh P; Rezaei N
Expert Rev Clin Immunol; 2023; 19(11):1361-1383. PubMed ID: 37578341
[TBL] [Abstract][Full Text] [Related]
23. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.
Rubin DB; Al Jarrah A; Li K; LaRose S; Monk AD; Ali AB; Spendley LN; Nikiforow S; Jacobson C; Vaitkevicius H
JAMA Neurol; 2020 Dec; 77(12):1536-1542. PubMed ID: 32777012
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study.
Maillet D; Belin C; Moroni C; Cuzzubbo S; Ursu R; Sirven-Villaros L; Di Blasi R; Thieblemont C; Carpentier AF
Neuro Oncol; 2021 Sep; 23(9):1569-1575. PubMed ID: 33822183
[TBL] [Abstract][Full Text] [Related]
25. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.
Korell F; Penack O; Mattie M; Schreck N; Benner A; Krzykalla J; Wang Z; Schmitt M; Bullinger L; Müller-Tidow C; Dreger P; Luft T
Front Immunol; 2022; 13():877477. PubMed ID: 35464403
[TBL] [Abstract][Full Text] [Related]
26. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.
Brammer JE; Braunstein Z; Katapadi A; Porter K; Biersmith M; Guha A; Vasu S; Yildiz VO; Smith SA; Buck B; Haddad D; Gumina R; William BM; Penza S; Saad A; Denlinger N; Vallakati A; Baliga R; Benza R; Binkley P; Wei L; Mocarski M; Devine SM; Jaglowski S; Addison D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429331
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Winkelmann M; Blumenberg V; Rejeski K; Quell C; Bücklein VL; Ingenerf M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
Ann Hematol; 2024 Jan; 103(1):259-268. PubMed ID: 37861736
[TBL] [Abstract][Full Text] [Related]
28. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
29. Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland.
Stolz S; Roncador M; Rösler W; Zenz T; Manz MG; Müller AMS; Widmer CC
Swiss Med Wkly; 2022 Jun; 152():w30186. PubMed ID: 35752964
[TBL] [Abstract][Full Text] [Related]
30. Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy.
Pu Y; Zhao Y; Qi Y; Liu Y; Zhang M; Xiao X; Lyu H; Meng J; Zhu H; Xu K; Han W; Zhao M
Int Immunopharmacol; 2024 Mar; 130():111761. PubMed ID: 38422769
[TBL] [Abstract][Full Text] [Related]
31. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies.
Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME
Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062
[TBL] [Abstract][Full Text] [Related]
32. [Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC].
Picard M; Sterin A; Bay JO; Courbon C; Moreau AS; Paul F; Pochon C; Tudesq JJ; Vicente C; Yakoub-Agha M; Yakoub-Agha I
Bull Cancer; 2023 Feb; 110(2S):S123-S131. PubMed ID: 35094839
[TBL] [Abstract][Full Text] [Related]
33. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
[TBL] [Abstract][Full Text] [Related]
34. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy.
Amidi Y; Eckhardt CA; Quadri SA; Malik P; Firme MS; Jones DK; Jain A; Danish HH; Rubin DB; Jacobson CA; Cash SS; Lee JW; Dietrich J; Westover MB
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450377
[TBL] [Abstract][Full Text] [Related]
35. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
36. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
37. A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma.
Beauvais D; Cozzani A; Blaise AS; Moreau AS; Varlet P; Gaggero S; Alidjinou EK; Vannod-Michel Q; Morschhauser F; Labalette M; Yakoub-Agha I; Mitra S
Curr Res Transl Med; 2022 May; 70(2):103331. PubMed ID: 34999480
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
39. Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma.
Grana A; Gut N; Williams K; Maakaron J; Porter K; William BM; Vasu S; Penza S; Brammer JE; Saad A; Puto M; Jaglowski SM; Roddy J
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):238-245. PubMed ID: 33132101
[TBL] [Abstract][Full Text] [Related]
40. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C
Clin Neurophysiol; 2024 Apr; 163():132-142. PubMed ID: 38733703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
